Used in clinical research as a selective Aurora A kinase inhibitor, showing potential in treating solid tumors by disrupting cell division in cancer cells. Demonstrates antitumor activity in preclinical models, particularly in cancers with specific genetic vulnerabilities. Currently under investigation in phase 1/2 trials for advanced solid malignancies, including ovarian and lung cancers. Designed to offer improved tolerability and targeted action compared to broader kinase inhibitors.